Model Number 222239 |
Device Problem
Contamination of Device Ingredient or Reagent (2901)
|
Patient Problem
No Clinical Signs, Symptoms or Conditions (4582)
|
Event Date 06/28/2023 |
Event Type
malfunction
|
Manufacturer Narrative
|
D1.Medical device brand name: bd bbl¿ chromagar¿ orientation and bbl¿ trypticase¿ soy agar w/5% sheep blood (tsa ii)-i plate¿ h3.A device evaluation is anticipated but has not yet begun.Upon completion of the investigation, a supplemental report will be filed.
|
|
Event Description
|
It was reported that bd bbl¿ chromagar¿ orientation and bbl¿ trypticase¿ soy agar w/5% sheep blood (tsa ii)-i plate¿ media was contaminated prior to use.This occurred 25 times.The following information was provided by the initial reporter: customer states they are getting contaminated plates right from the packaging itself.
|
|
Event Description
|
It was reported that bd bbl¿ chromagar¿ orientation and bbl¿ trypticase¿ soy agar w/5% sheep blood (tsa ii)-i plate¿.Media was contaminated prior to use.This occurred 25 times.The following information was provided by the initial reporter: customer states they are getting contaminated plates right from the packaging itself.
|
|
Manufacturer Narrative
|
H.6 investigation summary: during manufacturing of material 222239, media is formulated and sent through a high temperature short time sterilizer to remove bioburden.The petri dishes are subjected to uv radiation to decrease bioburden.The petri dishes are filled in a positive pressure hepa filtered environment.The filled plates are cooled and immediately wrapped into sleeves to decrease the introduction of microbes.Sleeves are then packaged into cartons and then transferred to a refrigerated truck (2 to 8 degrees c) for shipment to the distributor.Bd distributors are provided with the storage guidelines for the shipping and handling of bd media of 2 to 8 degrees c in a dark place.The batch history record for batch 3123271 was satisfactory and no quality notifications were generated during manufacturing and inspection.The release testing that is performed on this product does include bioburden testing.A sample of plates are incubated at 25 degrees c and at 35 degrees c for approximately 72 hours.All bioburden testing performed on this batch was satisfactory per bd internal procedures.Affected product does not have any sterility claims; the product is tested for bioburden prior to release to ensure that it conforms to product specifications.However, this does not ensure that the end-user will not receive a contaminated plate.The complaint history was reviewed and no other complaints have been taken on batch 3123271 for contamination.No retention samples for batch 3123271 were available for inspection.There were four photos received for investigation of this complaint.The first photo shows a plate (batch number and time stamp not visible) with contamination on the agar surface.The second photo shows a plate from batch 3123271 (time stamp 1901) with contamination on the agar surface.The third photo appears to show the same plate from the first photo.The fourth photo appears to show the same plate from the second photo.No return samples were available for investigation.This complaint can be confirmed for contamination.Bd has identified a contamination trend for this product and the investigation found opportunities for bioburden reduction in the manufacturing process.A capa (corrective and preventative actions) has been initiated and involves implementing additional cleaning events and evaluation of manufacturing procedures focused on in-process bioburden reduction.Additional trainings are part of the implementation with an ongoing training review for cleaning processes.Improvement in observation of contamination is expected as the capa progresses.Bd will continue to trend complaints for contamination.
|
|
Search Alerts/Recalls
|